Study to Assess the Safety, Tolerability and Immune Response Following Vaccination With Immunose™ FLU

Influenza, Human Clinical Trial

Official title:

A Phase I/II, Randomised, Placebo-controlled, Partially-blinded, Parallel-group Study to Assess the Safety, Tolerability and Immune Response Following Vaccination With Immunose™ FLU

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02998996
• Other study ID #: EURO 15-11
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: September 2016
• Est. completion date: June 1, 2017

Study information

• Verified date: October 2018
• Source: Eurocine Vaccines AB
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The main purpose of the this study is to evaluate the safety and tolerability of Immunose™ FLU based on Endocine™ and quadrivalent influenza antigen.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 162
• Est. completion date: June 1, 2017
• Est. primary completion date: June 1, 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 39 Years

Eligibility

Inclusion Criteria:

• Signed informed consent prior to any study related procedures.

• Male or female 18-39 years of age (both inclusive) at screening

• Subjects who the Investigator believes will comply with the requirements of the protocol.

• BMI: 18.0 and 30.0 kg/m2 (inclusive).

• Judged by the Investigator to have no serious illness based on medical history, physical examination, ECG, vital signs and blood and urine assessments at screening.

• From the signing of the informed consent until 2 months after the last vaccination (Visit 3 for group 1 to 4 and Visit 2 for group 5 and 6) female subjects have to use contraceptive methods with a failure rate of < 1% to prevent pregnancy (combined [oestrogen and progestogen containing] hormonal contraception associated with inhibition of ovulation [oral, intravaginal, transdermal], progestogen- only hormonal contraception associated with inhibition of ovulation [oral, injectable, implantable], intrauterine device [IUD], intrauterine hormone-releasing system [IUS], bilateral tubal occlusion, sexual abstinence). Any male partner should be willing to use condom or should be vasectomized.

Exclusion Criteria:

• Diagnosis of laboratory-confirmed influenza in the 2015/2016 season.

• Use of any investigational drug product within 3 months before screening or planned use during the study period, including the safety follow-up.

• Administration of an influenza vaccine during the 6 months before screening.

• Previously received another vaccine within 28 days before administration of the study vaccine, or is scheduled to receive another vaccine during the study period, excluding the safety follow-up.

• Any contra-indication to intramuscular administration of the influenza vaccine AdimFlu-S according to its prescribing information.

• Any contra-indication to administration of the influenza vaccine Fluenz Tetra according to its summary of product characteristics (SmPC).

• History of any anaphylactic reaction and/or serious allergic reaction following a vaccination, a proven hypersensitivity to any component of the study vaccine (e.g., to eggs or egg product as well as ovalbumin, chicken protein, chicken feathers, influenza viral protein, kanamycin, gentamycin and neomycin sulphate).

• Diagnosis of asthma with poor disease control as assessed by the Investigator.

• Potent immunosuppressive therapy including cytostatics, antibodies, drugs acting on immunophilins, interferons and other drugs used to prevent rejection of organ transplants, within 6 months before screening.

• Use of any parenteral or oral corticosteroids within 30 days prior to screening. Inhaled steroids are allowed.

• Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.

• Any progressive or severe neurologic disorder, seizure disorder or Guillain-Barré syndrome.

• History of Guillain-Barré syndrome within 6 weeks of receipt of prior inactivated influenza virus vaccine.

• Received blood, blood products and/or plasma derivatives or any administration of immunoglobulin preparation within the three months prior to Visit 2, or planned during the study.

• Participation in blood donation within 3 months or plasma donation within 1 month prior to Visit 2.

• History of substance or alcohol abuse within the past 2 years.

• History or any illness/condition that, in the opinion of the Investigator, might interfere with the results of the study or pose additional risk to the subjects due to participation in the study.

• Any positive result on screening for serum hepatitis B surface antigen, hepatitis C antibody and HIV.

• Pregnant or lactating female or intent to become pregnant during the clinic phase (up until and including Visit 4 for group 1 to 4 and Visit 3 for group 5 and 6) and for 2 months after the last vaccination.

• History of Bell's palsy.

• Ongoing regular use of intranasal sprays including corticosteroids and decongestants.

• Ongoing cough, sinusitis, allergic rhinitis, nasal polyps or obstruction, including septum deviation significant enough to prevent bilateral administration of study vaccine.

• Known bleeding diathesis, or any condition that may be associated with a prolonged bleeding time.

• Subjects that are prone to nosebleed.

Related Conditions & MeSH terms

• Influenza, Human

Intervention

Biological:
• 15 µg HA/strain and 1% Endocine™
intranasal administration
• 15 µg HA/strain and 2% Endocine™
intranasal administration
• 15 µg HA/strain
intranasal administration
• intramuscular comparator
intramuscular administration
• intranasal comparator
intranasal administration
• Placebo, Saline
intranasal administration

Locations

Country	Name	City	State
Sweden	Site 2	Linkoping
Sweden	Site 1	Uppsala

Sponsors (1)

Lead Sponsor	Collaborator
Eurocine Vaccines AB

Country where clinical trial is conducted

Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Local Tolerability - First Dose	Local tolerability, as measured by at least one of the administration site reactions swelling, redness, pain and pruritus, regardless of severity.	Pre-dose, and 15 and 120 min after study drug administration (Visit 2).
Primary	Local Tolerability - Second Dose (Group 1-4 Only)	Local tolerability, as measured by at least one of the administration site reactions swelling, redness, pain and pruritus, regardless of severity.	Pre-dose, and 15 and 120 min after second study drug administration (Visit 3).